Revuforj (Revumenib Citrate) | NCE-1 Intelligence & Market Opportunity

Revuforj

Revuforj is a drug used to treat relapsed or refractory acute leukemia. The treatment of acute leukemia is done with a lysine methyltransferase 2A gene translocation (KMT2A) in adults. This drug is also indicated for children 1 year and older whose disease has come back or has not improved after previous treatments.

The information outlined in the molecule details section below would help you evaluate Para IV filing opportunities early to secure a first-to-file advantage.

Molecule Details :

Molecule Name :

Revumenib Citrate
Innovator :

SYNDAX PHARMACEUTICALS INC
Approval Date :

15-Nov-24
NCE-1 Date :

15-Nov-28
NCE Date :

15-Nov-29
Dosage Form :

Oral Tablets
Strength :

25mg, 110mg and 160mg
Therapeutic Category :

Anticancer
Revenue ($M) :

125

Year-wise Projected Sales ($M) :

2026 :

261
2027 :

386
2028 :

555
2029 :

706
2030 :

863
2031 :

1027
2032 :

1188

Looking for this molecule for your next clinical research? Access regulatory-compliant comparators with assured timelines—delivered reliably through our global network.

Why Partner With Us

Supported 1000+ clinical trials globally
Provides services across regulatory, legal & clinical research
Unmatched intelligence on batches, expiry, spacing, and historical data from innovators
Integrated CRO services as part of our offerings
Insights on global pricing for smarter clinical trial supply decisions
Global sourcing capability across US, EU, South Africa, Canada, Japan, Australia, New Zealand, Southeast Asia, and other key markets

Revuforj

Molecule Details :

Year-wise Projected Sales ($M) :

Looking for this molecule for your next clinical research? Access regulatory-compliant comparators with assured timelines—delivered reliably through our global network.

Why Partner With Us

Login With

Are you sure want to logout from NCE Grid?